Business Development Deal Architecture
  • Search OnBioBD:

  • OnBioBD OldSkool NEWS:

    - OnBioVC 4Q11 Trend Analysis, now available
    - OnBioVC 1Q12 White Paper, now available
    - OnBioVC 1Q12 Trend Analysis, coming soon

  • FDA Registered Contract Manufacturer

Stemgent (Cambridge, MA) a commercial-stage supplier of stemcell related reagents and tools, closed a $5.6M Series B financing. Participants include HealthCare Ventures and Morgenthaler Ventures.

Cellular Dynamics (Madison, WA) a commercial-stage supplier of cardiomyocytes derived from, closed a $40.6M Series B financing. Participants include Tactics II Stem Cell Ventures, Equity Group Investments and Sixth Floor Investors.

Promethera Biosciences (Belgium) a development-stage stem cell therapy company focused on liver diseases, closed a $7.3M Series A financing. Participants include Vesalius Biocapital, Société Régionale d’Investissement de Wallonie, Life Sciences Partners, NivelInvest, Capital & Croissance, LRM, Vives and Sopartec. Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

Cellerix (Spain) a clinical-stage biopharma company focused on adult stem cell therapies for Crohn’s and other GI diseases, closed a $37.7M Series C financing. Participants include Ysios Capital Partners, Ventech, Roche Venture Fund and Novartis Venture Fund. Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

Fate Therapeutics (La Jolla, CA) a pre-clinical biopharma company focused on developing small molecule and biologic drug candidates to modulate stem cell pathways to stimulate tissue regeneration and blocking cancer growth, closed a $30M Series B financing. Participants include OVP Venture Partners, ARCH Venture Partners, Polaris Venture Partners and Venrock. Note: 2009 Year-in-Review Trend Analysis […]

Stemgent (Cambridge, MA) a commercial-stage supplier of stemcell related reagents and tools, closed a $14M Series A financing. Participants include HealthCare Ventures and Morgenthaler Ventures.

TaiGen Biotechnology (Taiwan) a clinical-stage pharmaceutical company focused on the treatment of infectious diseases, diabetic complications and cancer, closed a $37M Series C financing. Participants incldue MPM Capital, National Development Fund, YFY Group, Taiwan Sugar Corp., Yao-Hua Glass Management Commission and Taiwan Global BioFund.

Cardio3 BioSciences (Belgium) an early-stage company specialising in stem cell-based therapies for the treatment of cardiovascular disease, closed a $9.3M Series B financing. Participants include Hunza Ventures, Life Science Research Partners and Grifols.

OncoMed Pharmaceuticals (Redwood City, CA) clinical-stage company that discovers and develops novel therapeutics targeting cancer stem cells, closed a $154M Series B financing. Participants include Nomura Phase4 Ventures, US Venture Partners, Latterell Venture Partners, The Vertical Group, Morgenthaler Ventures, Adams Street Partners, DeNovo Ventures and Bay Partners.

Tengion (East Norriton, PA) early-stage regenerative medicine company focused on organ and tissue impairment, failure and loss, closed a $54M Series C financing. Participants include Safeguard Scientifics, Bain Capital, Johnson & Johnson Development Corp., Deerfield Partners, Quaker BioVentures, Oak Investment Partners, HealthCap and L Capital Partners.

Cellular Dynamics (Madison, WI) provider of drug screening and toxicity testing products based on induced pluripotent stem cell technology, closed a $18M Series A financing. Participants include Tactics II Stem Cell Ventures, Tactics II Ventures and the Wisconsin Alumni Research Foundation.

AcelleRX Therapeutics (Cleveland, OH) early-stage developer of therapeutics to rebuild tissue damaged from heart attack via stem cell approach, closed a$6.9M Series A financing. Participants include Triathlon Medical Ventures, Early Stage Partners, Fletcher Spaght Ventures, Reservoir Venture Partners, Blue Chip Venture, JumpStart and North Coast Angel Fund.

Histogenics (Waltham, MA) early-stage cartilage regeneration company developing products for joint repair, closed a $9M Series B financing. Participants include Boston Millennia Partners, Foundation Medical Partners, Altima Partners, Stryker Corporation and Inflection Point Partners.

« Previous Page« Previous Entries  Next Entries »Next Page »

to top of page...